Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter... see more

Recent & Breaking News (NDAQ:NVCN)

Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference

GlobeNewswire September 23, 2021

Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Simon Druker  September 16, 2021

Neovasc Announces FDA Approval of COSIRA-II Clinical Trial

GlobeNewswire September 16, 2021

This Emerging Medical Tech Could Help Millions of Underserved Patients

Stockhouse Editorial September 9, 2021

Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference

GlobeNewswire August 30, 2021

Sidoti Microcap Virtual Conference

Accesswire August 18, 2021

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

GlobeNewswire August 17, 2021

Neovasc Announces Second Quarter 2021 Financial Results

GlobeNewswire August 10, 2021

Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021

GlobeNewswire July 27, 2021

Neovasc (TSX:NVCN) announces new appointments in regulatory and clinical leadership

John Ballem  July 13, 2021

Neovasc Announces New Appointments in Regulatory and Clinical Leadership

GlobeNewswire July 13, 2021

Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology

GlobeNewswire June 18, 2021

IIROC Trade Resumption - NVCN

Canada NewsWire June 10, 2021

Neovasc Provides Corporate Update

GlobeNewswire June 10, 2021

IIROC Trading Halt - NVCN

Canada NewsWire June 10, 2021

Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

Trevor Abes  June 7, 2021

Neovasc Reducer System Receives First National Reimbursement in Europe

GlobeNewswire June 7, 2021

Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

Newsfile June 3, 2021

Neovasc (TSX:NVCN) receives NASDAQ notification regarding minimum bid price deficiency

John Ballem  May 25, 2021

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency 

GlobeNewswire May 25, 2021